AbbVie to buy biotech firm Aliada
AbbVie is buying Aliada Therapeutics for $1.4 billion. It is AbbVie’s third acquisition this year and its first in the neuroscience space since the firm bought Cerevel Therapeutics and its late-stage antipsychotic for $8.7 billion last year. AbbVie gains ALIA-1758, an anti-amyloid antibody currently in Phase I clinical trials as a treatment for Alzheimer’s disease, as well as Aliada’s modular delivery platform, which uses small proteins to deliver cargoes across the blood-brain barrier.
Authors
- Laura Howes (ORCID: https://orcid.org/0000-0003-2240-0745)
Publication Details
- Journal
- C&EN Global Enterprise
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1021/cen-10235-buscon17
- Primary Topic
- Biotechnology and Related Fields
- Type
- article
- Field-Weighted Citation Impact
- 0.00